Epidemiology of hepatitis B virus and/or hepatitis C virus infections among people living with human immunodeficiency virus in Africa: A systematic review and meta-analysis.
Journal
PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081
Informations de publication
Date de publication:
2022
2022
Historique:
received:
19
03
2022
accepted:
17
05
2022
entrez:
31
5
2022
pubmed:
1
6
2022
medline:
3
6
2022
Statut:
epublish
Résumé
Due to their common routes of transmission, human immunodeficiency virus (HIV) coinfection with hepatitis B virus (HBV) and/or hepatitis C virus (HCV) has become a major public health problem worldwide, particularly in Africa, where these viruses are endemic. Few systematic reviews report the epidemiological data of HBV and/or HCV coinfection with HIV in Africa, and none provided data on the case fatality rate (CFR) associated with this coinfection. This study was conducted to investigate the prevalence and case fatality rate of HBV and/or HCV infections among people living with human immunodeficiency virus (PLHIV) in Africa. We conducted a systematic review of published articles in PubMed, Web of Science, African Journal Online, and African Index Medicus up to January 2022. Manual searches of references from retrieved articles and grey literature were also performed. The meta-analysis was performed using a random-effects model. Sources of heterogeneity were investigated using subgroup analysis, while funnel plots and Egger tests were performed to assess publication bias. Of the 4388 articles retrieved from the databases, 314 studies met all the inclusion criteria. The overall HBV case fatality rate estimate was 4.4% (95% CI; 0.7-10.3). The overall seroprevalences of HBV infection, HCV infection, and HBV/HCV coinfection in PLHIV were 10.5% [95% CI = 9.6-11.3], 5.4% [95% CI = 4.6-6.2], and 0.7% [95% CI = 0.3-1.0], respectively. The pooled seroprevalences of current HBsAg, current HBeAg, and acute HBV infection among PLHIV were 10.7% [95% CI = 9.8-11.6], 7.0% [95% CI = 4.7-9.7], and 3.6% [95% CI = 0.0-11.0], respectively. Based on HBV-DNA and HCV-RNA detection, the seroprevalences of HBV and HCV infection in PLHIV were 17.1% [95% CI = 11.5-23.7] and 2.5% [95% CI = 0.9-4.6], respectively. Subgroup analysis showed substantial heterogeneity. In Africa, the prevalence of hepatotropic viruses, particularly HBV and HCV, is high in PLHIV, which increases the case fatality rate. African public health programs should emphasize the need to apply and comply with WHO guidelines on viral hepatitis screening and treatment in HIV-coinfected patients. PROSPERO, CRD42021237795.
Identifiants
pubmed: 35639675
doi: 10.1371/journal.pone.0269250
pii: PONE-D-22-08184
pmc: PMC9154112
doi:
Types de publication
Journal Article
Meta-Analysis
Systematic Review
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e0269250Subventions
Organisme : European & Developing Countries Clinical Trials Partnership
ID : EDCTP_TMA2019PF-2705
Pays : Netherlands
Déclaration de conflit d'intérêts
The authors have declared that no competing interests exist.
Références
Expert Opin Pharmacother. 2006 Sep;7(13):1835-43
pubmed: 16925509
Transfusion. 2020 Jan;60(1):106-116
pubmed: 31777096
Lancet Infect Dis. 2015 Jul;15(7):819-24
pubmed: 25957078
Int J Infect Dis. 2010 Dec;14(12):e1024-31
pubmed: 20870439
J Clin Epidemiol. 2012 Sep;65(9):934-9
pubmed: 22742910
Hepatology. 1999 Nov;30(5):1302-6
pubmed: 10534354
Clin Infect Dis. 2008 Dec 1;47(11):1479-85
pubmed: 18937580
Ann Intern Med. 2020 Sep 1;173(5):ITC33-ITC48
pubmed: 32866406
J Int AIDS Soc. 2016 Jun 09;19(1):20711
pubmed: 27293220
Lancet Glob Health. 2017 Dec;5(12):e1192-e1207
pubmed: 29074409
Lancet. 2010 Aug 7;376(9739):475-85
pubmed: 20650514
Clin Infect Dis. 2012 Apr;54(8):1167-78
pubmed: 22291098
Clin Infect Dis. 2014 Sep 15;59(6):765-73
pubmed: 24928290
J Hepatol. 2006;44(1 Suppl):S6-9
pubmed: 16352363
Lancet Infect Dis. 2016 Jul;16(7):797-808
pubmed: 26922272
Lancet. 2002 Dec 14;360(9349):1921-6
pubmed: 12493258
Lancet. 2000 Nov 25;356(9244):1800-5
pubmed: 11117912
Lancet. 2008 Nov 15;372(9651):1733-45
pubmed: 18817968
Antivir Ther. 2007;12 Suppl 3:H3-13
pubmed: 18284178
Gastroenterology. 2000 Jul;119(1):172-80
pubmed: 10889166
Addiction. 2019 Jan;114(1):150-166
pubmed: 30035835
BMC Infect Dis. 2013 Jun 24;13:288
pubmed: 23799878
Pan Afr Med J. 2013;14:44
pubmed: 23560127
J Hepatol. 2006;44(1 Suppl):S25-7
pubmed: 16338020
Lancet HIV. 2019 Dec;6(12):e831-e859
pubmed: 31439534
BMJ. 1997 Sep 13;315(7109):629-34
pubmed: 9310563
Clin Liver Dis. 2015 Feb;19(1):1-22
pubmed: 25454294
N Engl J Med. 2012 May 10;366(19):1749-52
pubmed: 22571198
Trop Med Int Health. 2011 Sep;16(9):1131-3
pubmed: 21672093
Clin Infect Dis. 2020 Dec 31;71(11):2799-2806
pubmed: 31813969
Clin Infect Dis. 2009 Jun 15;48(12):1763-71
pubmed: 19435436
Hepatology. 2009 May;49(5 Suppl):S138-45
pubmed: 19399813
Lancet Glob Health. 2017 Dec;5(12):e1208-e1220
pubmed: 29074410
PLoS One. 2017 Jun 14;12(6):e0179025
pubmed: 28614401
Clin Infect Dis. 2009 Nov 15;49(10):1605-15
pubmed: 19842982
Ann N Y Acad Sci. 2008;1136:161-71
pubmed: 17954679
J Viral Hepat. 2010 Aug;17(8):578-87
pubmed: 19818002
Hepatology. 2000 Nov;32(5):1145-53
pubmed: 11050068
BMJ. 2003 Sep 6;327(7414):557-60
pubmed: 12958120
Int J STD AIDS. 2017 Jun;28(7):636-650
pubmed: 26868158